Edesa Biotech files prospectus supplement for up to $4.0M ATM offering through H.C. Wainwright

Edesa Biotech, Inc.

ATM offering for up to $4,006,544 of common shares through H.C. Wainwright.
Previously sold $837,134 under existing ATM agreement from October 2024.
New shelf registration statement (S-3, File No. 333-288966) declared effective September 9, 2025.
Legal opinion from Fasken Martineau DuMoulin LLP on share validity included as exhibit.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.